Preventing breast cancer in women with schizophrenia

Acta Psychiatrica Scandinavica

Volumn 123, Issue 2, 2011, Pages 107-117

  Seeman, M V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alcohol; Antipsychotics; Lactation; Obesity; Prolactin; Smoking

Indexed keywords

AMISULPRIDE; CAFFEINE; METFORMIN; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PROLACTIN; RALOXIFENE; RISPERIDONE; TAMOXIFEN;

ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; BREAST FEEDING; CANCER RISK; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DIABETES MELLITUS; DIET; DRINKING BEHAVIOR; EXERCISE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERPROLACTINEMIA; MAMMOGRAPHY; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSOCIAL CARE; RISK FACTOR; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; SOCIAL STATUS; WEIGHT REDUCTION;

ALCOHOL DRINKING; ANTIDEPRESSIVE AGENTS; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; HUMANS; HYPERPROLACTINEMIA; OBESITY; PARITY; PREGNANCY; RISK FACTORS; SCHIZOPHRENIA; SMOKING; SOCIOECONOMIC FACTORS;

EID: 78650799605     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01626.x     Document Type: Article

References (125)

1. American Cancer Society. Accessed Aug. 21, 2010.
2. Dalton SO, Schüz J, Engholm G et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: summary of findings. Eur J Cancer 2008;44:2074-2085.
3. Barak Y, Levy T, Achiron A, Aizenberg D. Breast cancer in women suffering from serious mental illness. Schizophr Res 2008;102:249-253.
4. National Cancer Institute. Accessed Aug. 21, 2010.
5. Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence. A systematic review of clinical studies. Schizophr Res 2009;114:6-16.
6. Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N. Psychiatric medication-induced obesity: a review. Obes Rev 2004;5:115-121.
7. Mccreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-539.
8. Maccabe JH, Koupil I, Leon DA. Lifetime reproductive output over two generations in patients with psychosis and their unaffected siblings: the Uppsala 1915-1929 Birth Cohort Multigenerational Study. Psychol Med 2009;39:1667-1676.
9. Ystrom E, Niegel S, Klepp K-I, Vollrath ME. The impact of maternal negative affectivity and general self-efficacy on breastfeeding: the Norwegian Mother and Child Cohort Study. J Pediatr 2008;152:68-72.
10. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl. 1):1-93.
11. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701.
12. Green AI, Brown ES. Comorbid schizophrenia and substance abuse. J Clin Psychiatry 2006;67:e08.
13. Adly L, Hill D, Sherman ME et al. Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. Int J Cancer 2006;119:2402-2407.
14. Kirschner MA, Schneider G, Ertel NH, Worton E. Obesity, androgens, estrogens, and cancer risk. Cancer Res 1982;42:3281s-3285s.
15. Mckeown-Eyssen GE, Rogers-Melamed I, Clarke EA. Estrogen receptor status of breast cancer in Ontario. Can Med Assoc J 1985;133:997-1000.
16. Fortunati N, Catalano MG, Boccuzzi G, Frairia R. Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol 2010;316:86-92.
17. Wei S, Schmidt MD, Dwyer T, Norman RJ, Venn AJ. Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring) 2009;17:1070-1076.
18. Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010;1:443-451.
19. Brown KA, Simpson ER. Obesity and breast cancer: progress to understanding the relationship. Cancer Res 2010;70:4-7.
20. Schlienger JL, Luca F, Vinzio S, Pradignac A. Obesity and cancer. Rev Med Interne 2009;30:776-782.
21. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009;20:193-201.
22. Rose DP, Vona-Davis L. Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther 2009;9:1091-1101.
23. Percik R, Stumvoll M. Obesity and cancer. Exp Clin Endocrinol Diabetes 2009;117:563-566.
24. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010;66:33-38.
25. Schernhammer ES, Tworoger SS, Eliassen AH et al. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 2007;14:721-732.
26. Ahn J, Schatzkin A, Lacey JV et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007;167:2091-2102.
27. Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr Res 2010;119:145-152.
28. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2 - an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010;118:4-8.
29. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16: 1103-1123.
30. Call R, Grimsley M, Cadwallader L et al. Insulin - carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med 2010;122:158-165.
31. Mckibbin CL, Golshan S, Griver K, Kitchen K, Wykes TL. A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis. Schizophr Res 2010;121:203-206.
32. Chochinov HM, Martens PJ, Prior HJ, Fransoo R, Burland E, Need to Know Team. Does a diagnosis of schizophrenia reduce rates of mammography screening? A Manitoba population-based study. Schizophr Res 2009;113:95-100.
33. Werneke U, Horn O, Maryon-Davis A, Wessely S, Donnan S, Mcpherson K. Uptake of screening for breast cancer in patients with mental health problems. Epidemiol Community Health 2006;60:600-605.
34. Schueler KM, Chu PW, Smith-Bindman R. Factors associated with mammography utilization: a systematic quantitative review of the literature. J Womens Health (Larchmt) 2008;17:1477-1498.
35. Fair AM, Wujcik D, Lin JM et al. Obesity, gynecological factors, and abnormal mammography follow-up in minority and medically underserved women. J Womens Health (Larchmt) 2009;18:1033-1039.
36. Dursun SM, Wildgust HJ, Strickland P, Goodwin GM, Citrome L, Lean M. The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness. J Psychopharmacol 2008;22(Suppl. 2):3-5.
37. Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. J Endocrinol 2009;203:99-110.
38. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008;22(Suppl. 2):46-55.
39. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-135.
40. Ben-Jonathan N, Christopher R, Lapensee CR, Lapensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev 2008;29:1-41.
41. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004;64:6814-6819.
42. Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:895-899.
43. Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol Cell Endocrinol 2009;307:1-7.
44. Lapensee EW, Ben-Jonathan N. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr Relat Cancer 2010;17:R91-R107.
45. Rasmussen LM, Frederiksen KS, Din N et al. Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocr Relat Cancer 2010;17:809-822.
46. Lee MS, Song HC, An H et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci 2010;64:19-27.
47. Rowther FB, Richardson A, Clayton RN, Farrell WE. Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells. Neuroendocrinology 2010;91:256-267.
48. Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008;69:385-391.
49. O'keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;2(Suppl):70-75.
50. Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 2009;35:937-948.
51. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint oestrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006;8:R43.
52. Stuebe A. The risks of not breastfeeding for mothers and infants. Rev Obstet Gynecol 2009;2:222-231.
53. Anderson PO. Drugs and breast feeding. Semin Perinatol 1979;3:271-278.
54. Gentile S. Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry 2008;69:666-673.
55. Moretti ME. Psychotropic drugs in lactation - Motherisk Update 2008. Can J Clin Pharmacol 2009;16:e49-e57.
56. Fríguls B, Joya X, García-Algar O, Pallás CR, Vall O, Pichini S. A comprehensive review of assay methods to determine drugs in breast milk and the safety of breastfeeding when taking drugs. Anal Bioanal Chem 2010;397:1157-1179.
57. Conlon MS, Johnson KC, Bewick MA, Lafrenie RM, Donner A. Smoking (active and passive), N-acetyltransferase 2, and risk of breast cancer. Cancer Epidemiol 2010;34:142-149.
58. Forchuk C, Norman R, Malla A et al. Schizophrenia and the motivation for smoking. Perspect Psychiatr Care 2002;38:41-49.
59. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010;119:101-109.
60. Zhang XY, Zhang RL, Pan M, Chen DC, Xiu MH, Kosten TR. Sex difference in the prevalence of smoking in Chinese schizophrenia. J Psychiatr Res 2010;44:986-988.
61. Bobes J, Arango C, Garcia-Garcia M, Rejas J, Clamors Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010;71:280-286.
62. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2010; 6:CD007253.
63. Colditz GA, Manson JE, Hankinson SE. The Nurses' health study: 20-year contribution to the understanding of health among women. J Women's Health 1997;6:49-62.
64. Ganmaa D, Willett WC, Li TY et al. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. Int J Cancer 2008;122:2071-2076.
65. Kotsopoulos J, Eliassen AH, Missmer SA et al. Relationship between caffeine intake and plasma sex hormone concentrations in premenopausal and postmenopausal women. Cancer 2009;115:2765-2774.
66. Hughes JR, Mchugh P, Holtzman S. Caffeine and schizophrenia. Psychiatr Serv 1998;49:1415-1417.
67. Drake RE. Management of substance use disorder in schizophrenia patients: current guidelines. CNS Spectr 2007;10(Suppl. 17):27-32.
68. Zhang SM, Lee IM, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007;165:667-676.
69. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 2007;99:64-76.
70. Hamajima N, Hirose K, Tajima K et al. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58, 515 women with breast cancer and 95, 067 women without the disease. Br J Cancer 2002;87:1234-1245.
71. Lubman DI, King JA, Castle DJ. Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry 2010;22:191-201.
72. Bernstein L. Identifying population-based approaches to lower breast cancer risk. Oncogene 2008;27(Suppl. 2):S3-S8.
73. Neilson HK, Friedenreich CM, Brockton NT, Millikan RC. Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol Biomarkers Prev 2009;18:11-27.
74. Brandt C, Pedersen BK. The role of e-induced myokines in muscle homeostasis and the defense against chronic diseases. J Biomed Biotechnol 2010. Article ID 520258, 6 pages, 2010. doi.
75. Fair AM, Montgomery K. Energy balance, physical activity, and cancer risk. Methods Mol Biol 2009;472:57-88.
76. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat 2006;97:97-106.
77. Monninkhof EM, Elias SG, Vlems FA et al. Physical activity and breast cancer: a systematic review. Epidemiology 2007;18:137-157.
78. Gorczynski P, Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev 2010;5:CD004412.
79. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt) 2009;18:883-893.
80. Innos K, Mägi M, Tekkel M, Aareleid T. Place of residence predicts breast cancer stage at diagnosis in Estonia. Eur J Public Health 2010. doi:. [Epub ahead of print]
81. Carlsen K, Høybye MT, Dalton SO, Tjønneland A. Social inequality and incidence of and survival from breast cancer in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008;44:1996-2002.
82. Tran E, Rouillon F, Loze JY et al. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer 2009;115:3555-3562.
83. Sharma A, Ngan S, Nandoskar A et al. Schizophrenia does not adversely affect the treatment of women with breast cancer: a cohort study. Breast 2010;19:410-412.
84. Chubak J, Bowles EJ, Terry MB, Trentham-Dietz A, Buist DS. Antidepressant medications and change in mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2009;18:676-679.
85. Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 2010;43:122-129.
86. Sale A, Berardi N, Maffei L. Enrich the environment to empower the brain. Trends Neurosci 2009;32:233-239.
87. Dixon LB, Dickerson F, Bellack AS et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010;36:48-70.
88. Shean GD. Evidence-based psychosocial practices and recovery from schizophrenia. Psychiatry 2009;72:307-320.
89. Pajonk F-G, Wobrock T, Gruber O et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 2010;67:133-143.
90. Kumari V, Antonova E, Fannon D et al. Beyond dopamine: functional MRI predictors of responsiveness to cognitive behaviour therapy for psychosis. Front Behav Neurosci 2010;4:4.
91. Amminger GP, Schäfer MR, Papageorgiou K et al. Long-chain Ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-154.
92. Saravane D, Feve B, Frances Y et al. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale 2009;35:330-339.
93. Roberts L, Roalfe A, Wilson S, Lester H. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract 2007;24:34-40.
94. Cuzick J, Forbes JF, Sestak I et al. Long-term results of tamoxifen prophylaxis for breast cancer 96 month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-282.
95. Baumann CK, Castiglione-Gertsch M. Clinical use of selective oestrogen receptor modulators and down regulators with the main focus on breast cancer. Minerva Ginecol 2009;61:517-539.
96. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004;18:CD002748.
97. Harvie M, Howell A, Vierkant RA et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2005;14:656-661.
98. Henderson DC, Borba CP, Daley TB et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 2006;18:99-105.
99. Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120:18-33.
100. Beebe LH. Obesity in schizophrenia: screening, monitoring, and health promotion. Perspect Psychiatr Care 2008;44:25-31.
101. Lindenmayer JP, Khan A, Wance D, Maccabee N, Kaushik S, Kaushik S. Outcome evaluation of a structured educational wellness program in patients with severe mental illness. J Clin Psychiatry 2009;70:1385-1396.
102. Bushe C, Haddad P, Peveler R, Pendlebury J. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005;6l:28-35.
103. Lim S, Norman R, Clifton P, Noakes M. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. Nutr Metab Cardiovasc Dis 2010. doi: [Epub ahead of print].
104. Bushe CJ, Bradley AJ, Doshi S, Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract 2009;63:1743-1761.
105. Beebe LH, Burk R, Mcintyre K et al. Motivating persons with schizophrenia spectrum disorders to exercise: Rationale and design. Clin Schizophr Relat Psychoses 2009;3:111-116.
106. Anderson AS, Caswell S. Obesity management - an opportunity for cancer prevention. Surgeon 2009;7:282-285.
107. Evins AE, Cather C, Deckersbach T et al. A double-blind placebo-controlled trial of buproprion sustained smoking or smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25:218-225.
108. George TP, Ziedonis DM, Feingold A et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-1842.
109. Lybrand J, Caroff S. Management of schizophrenia with substance use disorders. Psychiatr Clin North Am 2009;32:821-833.
110. Favrod J. Motivational interventions: psychosis and cannabis. Encephale 2009;35(Suppl. 6):S209-S213.
111. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry 2009;17:24-34.
112. Linos E, Willett WC. Diet and breast cancer risk reduction. J Natl Compr Canc Netw 2007;5:711-718.
113. Michels KB, Mohllajee AP, Roset-Bahmanyar E et al. Diet and breast cancer: a review of the prospective observational studies. Cancer 2007;109(Suppl):2712-2749.
114. Cho E, Chen WY, Hunter DJ et al. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med 2006;166:2253-2259.
115. Shrubsole MJ, Lu W, Chen Z et al. Drinking green tea modestly reduces breast cancer risk. J Nutr 2009;139:310-316.
116. López-Miranda J, Pérez-Jiménez F, Ros E et al. Olive oil and health: summary of the II International Conference on olive oil and health consensus report, Jaén and Córdoba (Spain) 2008. Nutr Metab Cardiovasc Dis 2010;20:284-294.
117. Bjørge T, Lukanova A, Jonsson H et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010;19:1737-1745.
118. Kahn R, Alperin P, Eddy D et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-1374.
119. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-1308.
120. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2005;161:1324-1333.
121. Lumachi F, Frigo AC, Basso U, Tombolan V, Ermani M. Oestrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis. Menopause 2010;17:524-528.
122. Gaffield ME, Culwell KR, Ravi A. Oral contraceptives and family history of breast cancer. Contraception 2009;80:372-380.
123. Banks E, Canfell K. Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. Breast Cancer Res 2010;12:103.
124. Saha S, Chant D, Mcgrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-1131.
125. Catts VS, Catts SV, O'toole BI, Frost AD. Cancer incidence in patients with schizophrenia and their first degree relatives- a meta-analysis. Acta Psychiatr Scand 2008;117:323-336.